By Counterforce Health Team in Blenrep (belantamab mafodotin) —

How to Get Blenrep (belantamab mafodotin) Covered by Humana in Florida: Timeline, Appeals & Clinical Trial Access

Answer Box: Getting Blenrep Coverage Through Humana in Florida

Blenrep (belantamab mafodotin) was withdrawn from the U.S. market in 2022 and is only available through clinical trials or FDA expanded access programs. Humana Medicare Part D plans explicitly exclude withdrawn drugs from coverage. Your fastest path: 1) Contact your oncologist about active clinical trials, 2) Request FDA expanded access if trials aren't available, and 3) Submit a formulary exception request to Humana for any investigational access costs not covered by the study sponsor.

First step today: Call your multiple myeloma specialist to discuss BCMA-targeted alternatives (CAR-T therapy, bispecific antibodies) that are FDA-approved and covered by Humana.

Table of Contents

Why Blenrep Coverage is Complex

Blenrep (belantamab mafodotin) presents unique coverage challenges for Humana members in Florida. GSK voluntarily withdrew the drug from the U.S. market in November 2022 due to efficacy concerns, though it has since resubmitted to the FDA with a PDUFA date of October 23, 2025.

Current status affects coverage:

  • No commercial availability means standard prior authorization doesn't apply
  • Humana Part D exclusions specifically state that withdrawn drugs are not covered
  • Clinical trial or expanded access are the only legal pathways to obtain the drug
Note: Even if Blenrep receives FDA re-approval in late 2025, Humana will need time to conduct formulary reviews and establish prior authorization criteria.

Pre-Submission Preparation (0-2 Days)

Before pursuing any coverage path, gather these essential documents:

Patient Information Checklist:

  • Humana member ID and Evidence of Coverage documents
  • Complete multiple myeloma treatment history
  • Prior BCMA-targeted therapy responses (if any)
  • Recent imaging and laboratory results
  • ICD-10 diagnosis codes (C90.0- series for multiple myeloma)

Clinical Documentation:

  • Oncologist's treatment notes documenting relapsed/refractory status
  • Evidence of prior therapy failures or intolerances
  • ECOG performance status assessment
  • Ophthalmologic clearance (required for BCMA-targeted therapies due to ocular toxicity)

Clinical Trial Access Path

Since Blenrep is withdrawn, clinical trials offer the most direct access route. GSK and academic centers are conducting studies as part of the FDA resubmission process.

How to Find Active Trials:

  1. Search ClinicalTrials.gov using "belantamab mafodotin" and "Florida"
  2. Contact major Florida cancer centers:
    • Moffitt Cancer Center (Tampa)
    • Sylvester Comprehensive Cancer Center (Miami)
    • UF Health Cancer Center (Gainesville)

Insurance Considerations:

  • Medicare Part B may cover routine trial costs (monitoring, standard care)
  • Drug costs are typically covered by the study sponsor
  • Humana coordination may be needed for non-trial medical expenses
Tip: Clinical trials often provide the drug at no cost, making this the most economical access route.

Expanded Access Program Route

If clinical trials aren't available or appropriate, FDA expanded access (compassionate use) may be an option for seriously ill patients.

Eligibility Requirements:

  • Serious or life-threatening condition
  • No comparable or satisfactory alternative treatments
  • Potential benefit justifies risks
  • Patient unable to obtain drug through clinical trial

Application Process:

  1. Physician initiates expanded access request with FDA
  2. FDA review typically takes 30 days (can be expedited to 24 hours for emergencies)
  3. IRB approval required at treating institution
  4. GSK approval needed as the manufacturer

Insurance Coverage for Expanded Access: Humana's coverage of expanded access drugs varies. Submit a formulary exception request with strong medical necessity documentation.

Humana Formulary Exception Process (1-5 Days)

Even for investigational access, you may need Humana coverage for associated costs not covered by trials or expanded access programs.

Coverage at a Glance

Requirement What It Means Where to Find It Timeline
Medical Necessity Letter Oncologist documents why Blenrep is essential Provider must submit Required
Prior Authorization Form Prescription Drug Coverage Determination Request Humana website Submit with letter
Supporting Documentation Treatment history, failure of alternatives Medical records Include with request
Submission Method Fax: 877-486-2621 or online portal Provider resources 72-hour standard review

Step-by-Step Exception Process

  1. Gather Documentation (Day 1)
    • Your oncologist completes the medical necessity letter
    • Include evidence that covered alternatives have failed or are inappropriate
    • Document specific medical reasons why Blenrep is needed
  2. Submit Request (Day 1-2)
    • Provider submits via Humana provider portal or fax
    • Include all supporting documentation
    • Request expedited review if urgent (24-hour decision required)
  3. Humana Review (Day 2-4)
    • Standard review: 72 hours from receipt
    • Expedited review: 24 hours if health could be seriously harmed by delay
    • Additional information requests may extend timeline

If Denied: Florida Appeal Timeline

Florida residents with Humana Medicare Advantage have specific appeal rights when coverage is denied.

Internal Appeal Process

Level 1: Plan Reconsideration

  • Filing deadline: 65 days from denial notice
  • Decision timeline: 72 hours for expedited drug appeals, 7-30 days standard
  • How to file: Call Humana, submit written request, or use online portal
  • Required: Physician statement supporting medical necessity

Expedited Appeals for Oncology: If your oncologist certifies that waiting could "seriously jeopardize your life or health," Humana must provide an expedited decision within 72 hours.

External Review Options

Level 2: Independent Review Entity (IRE)

  • When to file: After Humana denies your internal appeal
  • Filing deadline: 65 days from plan denial
  • Timeline: 72 hours for expedited reviews
  • Cost: Free to patient

Florida-Specific Resources:

  • Florida Department of Financial Services: 1-877-MY-FL-CFO for insurance complaints
  • External review contractor: Contact through CMS Medicare appeals portal

Alternative BCMA-Targeted Therapies

While pursuing Blenrep access, discuss these FDA-approved BCMA-targeted options with your oncologist:

CAR-T Cell Therapies (Covered by Humana):

  • Abecma (ide-cel): First-line BCMA CAR-T therapy
  • Carvykti (cilta-cel): Often preferred for certain patient populations

Bispecific Antibodies:

  • Tecvayli (teclistamab): Weekly subcutaneous injection
  • Elrexfio (elranatamab): Biweekly dosing after initial schedule

These alternatives typically have established Humana coverage pathways and don't require the complex access routes needed for withdrawn drugs.

From our advocates: We've seen patients successfully transition to CAR-T therapy while maintaining their spot on clinical trial waiting lists. This approach ensures continuous treatment while keeping future options open. Always coordinate with your oncology team to avoid conflicts between different treatment protocols.

Timeline Summary Table

Phase Timeline Key Actions Success Factors
Preparation 0-2 days Gather documents, contact oncologist Complete medical records
Clinical Trial Search 1-7 days Search databases, contact centers Geographic accessibility
Expanded Access 30+ days FDA application, IRB approval Serious medical need
Humana Exception 1-5 days Submit formulary exception Strong medical necessity
Internal Appeal 65 days to file Plan reconsideration Physician support
External Review 65 days to file Independent medical review Documented medical necessity

FAQ: Common Questions

Q: How long does Humana prior authorization take in Florida? A: Standard formulary exceptions require 72 hours for decisions, but since Blenrep is withdrawn, you'll likely need clinical trial or expanded access first.

Q: What if Blenrep is non-formulary when it returns to market? A: Humana will establish new prior authorization criteria. Current BCMA-targeted therapies suggest coverage will require prior therapy failures and specific multiple myeloma subtypes.

Q: Can I request an expedited appeal for urgent multiple myeloma treatment? A: Yes, if your physician certifies that delay could seriously harm your health, Humana must decide within 72 hours.

Q: Does step therapy apply if I've failed treatments outside Florida? A: Treatment history from any state counts toward step therapy requirements. Ensure your new Florida oncologist has complete records from previous providers.

Q: What happens if FDA re-approves Blenrep in late 2025? A: Humana will need 60-90 days to conduct formulary reviews and establish coverage criteria. Existing clinical trial participants may have transition coverage options.

Q: Are there financial assistance programs for BCMA-targeted therapies? A: Yes, manufacturer copay assistance and foundation grants are available for approved alternatives like CAR-T therapies. Clinical trials typically provide investigational drugs at no cost.

About Counterforce Health: Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to create targeted, evidence-backed rebuttals. For complex cases like withdrawn drugs requiring expanded access, their platform helps identify the specific documentation payers expect and streamlines the appeals process with payer-specific workflows and deadline tracking.

While Blenrep's withdrawn status creates unique challenges, understanding Humana's processes and Florida's appeal rights puts you in the strongest position for eventual coverage. Work closely with your oncology team to explore all available pathways, and don't hesitate to leverage Counterforce Health's expertise when navigating complex coverage decisions.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual circumstances, plan details, and current FDA approvals. Always consult with your healthcare provider and insurance plan directly for coverage determinations. For additional help with Florida insurance appeals, contact the Florida Department of Financial Services at 1-877-MY-FL-CFO.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.